Dr. Jordi Rello, head of the Clinical Research and Innovation in Pneumonia & Sepsis at Vall d’Hebron Institute of Research (VHIR), was reelected chair until 2016 of the Critically Ill Patients group of the "https://www.escmid.org/" European Society of Clinical Microbiology and Infectious Diseases (ESCMID).VHIR’s researcher founded the group 3 years ago and since then they have been very active, with several educational and research activities. They are currently conducting an international multicenter study with the aim to assess new definitions of respiratory diseases in the intensive care units for the Centers for Disease Control (CDC). Vall d’Hebron participates in the study, together with the Hospital General Universitario de Alicante and more than 30 hospitals from Australia, China, Lebanon, Turkey, Greece, Croatia, Italy, Slovenia, France and Portugal. They are also leading, at Vall d’Hebron and with the participation of European, American and Australian researchers, the first guidelines of clinical practice about the use of nebulized antibiotics in patients with artificial ventilation, with the collaboration of the Cochrane.The mission of the "https://www.escmid.org/research_projects/study_groups/critically_ill_patients/" Critically Ill Patients group is to promote knowledge of infections of critically ill and ICU-admitted patients, with focus on infections from multidrug-resistant pathogens. The group consists of 35 active members, with the representation of intensivists, infectologists, microbiologists, and specialists in nursery, pharmacology, surgery and respiratory diseases.